TrialCancer communications (London, England)2026

IMMUNOSARC II Master Trial: Phase II Study of Sunitinib and Nivolumab in Clear Cell Sarcoma Cohort.

Javier Martin-Broto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.